In the last few years, targeting co-inhibitory receptors with monoclonal antibodies has shown impressive results in tumor regression and overall survival, leading to the approval of anti-CTLA-4, anti-PD-1, and anti-PD-L1 in numerous cancers [3]. This evidence concerns the gene CTLA4 and cancer.